An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53

Gene Therapy

Volumn 9, Issue 5, 2002, Pages 345-352

  Nikitina, E Y ^a   Chada, S ^b   Muro Cacho, C ^a   Fang, B ^c   Zhang, R ^c   Roth, J A ^c   Gabrilovich, D I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Introgen Therapeutics Inc   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenoviral vector; Dendritic cells; Immunotherapy; p53

Indexed keywords

ADENOVIRUS VECTOR; CD40 ANTIGEN; NEUTRALIZING ANTIBODY; PROTEIN P53; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL FUNCTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; GENETIC TRANSDUCTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; SARCOMA CELL; TUMOR REJECTION; WILD TYPE;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GENE THERAPY; GENES, P53; GENETIC VECTORS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SARCOMA, EXPERIMENTAL; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 85047698841     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301670     Document Type: Article

References (40)

1. DNA damage induces phosphorylation of the amino terminus of p53
2. WAF1, a potential mediator of p53 tumor suppression
3. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
4. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression
5. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
6. A model for p53-induced apoptosis
7. p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos, and tumors
8. Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages
9. The emerging p53 gene family
10. The p53 tumour suppressor gene
11. Mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells
12. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
13. Targeting p53 as a general tumor antigen
14. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines
15. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors
16. IL-12 and mutant p53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer
17. p53, a potential target for tumor-directed T cells
18. Bone-marrow derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
19. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide
20. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using auologous dendritic cells
21. Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type determinant
22. Dendritic cells transduced with wild type p53 gene elicit potent antitumor immune responses
23. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients
24. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes
25. P53: A target for T-cell-mediated immunotherapy
26. The mode of presentation and route of administration are critical for the induction of immune response to p53 and antitumor immunity
27. Dendritic cells: Development, function and potential use for cancer immunotherapy
28. Dendritic cell vaccines for cancer immunotherapy
29. Experimental vaccine strategies for cancer immunotherapy
30. Effective repeat administration with adenovirus vectors to the muscle
31. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
32. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms
33. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
34. Regulation of dendritic cell system by tumor
35. Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer
36. Dendritic cell activation induced by various stimuli, eg exposure to microorganisms, their products, cytokines, and simple chemicals as well as adhesion to extracellular matrix
37. Dendritic cells: Expansion and differentiation with hematopoietic growth factors
38. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
39. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines
40. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset